Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long‐term use

• DOI: 10.1002/ptr.6123
• Publication Date: 2018-05-28T08:35:08Z
• Authors: Ashish Dogra; Shipra Bhatt; Asmita Magotra; Anjna Sharma; Pankul Kotwal; Abhishek Gour; Priya Wazir; Gurdarshan Singh; Utpal Nandi
• Keywords: Daclatasvir; Concomitant

Curcumin, a natural diarylheptanoid, is extensively used as food additive or dietary supplement on the regular basis. It known to have potential encumber drug transporters and hepatic metabolizing enzymes that lead pharmacokinetic interactions with food. Daclatasvir new orally acting for treatment of chronic Hepatitis C Virus infections. This substrate P-glycoprotein CYP3A4 are involved in major interaction. Hence, studies' aim assess any possible interactions. Pharmacokinetic studies daclatasvir presence absence curcumin were carried out Wistar rats following oral administration. Parallelly, pharmacokinetics was also determined ketoconazole quinidine. Studies revealed plasma level not altered significantly during concomitant single dose administration curcumin, whereas decreased upon pretreatment 7 days at high level. Ketoconazole quinidine markedly increase exposure daclatasvir. can be concluded adjustment unlikely required intermittent use low but cautious dose.